Heron Therapeutics Inc (NASDAQ: HRTX) stock closed at $3.22 on 6/17/24 after a major decline of -10.4%. Moreover, above average trading volume at 126% of normal accompanied the decline. The stock has declined -10.4% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
HRTX is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Heron Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment